Rocket Companies returns to the earnings table on August 6 having already absorbed one disappointing print last week, with short sellers maintaining elevated positions and the stock down 18% over the past month.
The short interest story has evolved materially since the previous two previews published ahead of the July 30 report. Those notes flagged a rapid buildup from roughly 110 million to 140 million shares short — a 25% week-on-week surge. That position has held: short interest remains at 14.6% of the free float as of July 30, essentially unchanged after the July 30 print delivered a 5.8% single-day decline. Bears did not cover into the drop. The ORTEX short score has also edged up to 62.7, its highest level in the 10-day window, while days-to-cover sit at 5.1 sessions per the latest FINRA filing. Yet the borrow market continues to show no sign of strain. Availability is running at around 302% — three shares available to lend for every one already borrowed — and the cost to borrow remains negligible at 0.46%. That combination means shorts are dug in, but not squeezed.
Options traders are tilting the other way. The put/call ratio has fallen to 0.31, more than a full standard deviation below its 20-day average of 0.36 and near the lower end of its 52-week range of 0.22 to 0.71. That skew toward calls is more pronounced than it was ahead of the July 30 report, suggesting options positioning has turned more constructive even as short interest has stayed elevated — a divergence that sharpened after last week's sell-off rather than before it.
The analyst backdrop provides some context for that optimism. Morgan Stanley upgraded the stock to Overweight on July 16 with a $19 target, a meaningful call given the stock now trades at $12.90. Other bellwether firms have been more cautious: JP Morgan trimmed its target to $15.50 while holding Neutral, and Barclays cut to $17 while staying Overweight. The consensus sits at hold, with the mean target implying roughly 45–50% upside from current levels. Bulls point to Rocket's dominant origination share and the potential operating leverage from its Mr. Cooper acquisition. Bears note that the downside target of $14 is already above the current price, that MSR valuations remain vulnerable, and that rate sensitivity has not gone away.
T. Rowe Price added 11.7 million shares in the quarter to June 30, making it the most aggressive institutional accumulator in the recent filing period. FMR added 10.1 million and Amundi 8.3 million. The institutional flow stands in contrast to insider behavior: executives across the COO, CTO, and CMO roles sold shares in April at prices ranging from $14 to $15, well above where the stock sits today.
The August 6 print is less a test of whether Rocket can originate mortgages and more a test of whether the Mr. Cooper integration is delivering the margin profile that justifies rebuilding a position after last week's drop at a 15x earnings multiple that assumes a clean recovery in volumes.
See the live data behind this article on ORTEX.
Open RKT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
